BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 36129842)

  • 1. Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.
    Machet A; Poudou C; Tomowiak C; Gastinne T; Gardembas M; Systchenko T; Moya N; Debiais C; Levy A; Gruchet C; Sabirou F; Noel S; Bouyer S; Leleu X; Delwail V; Guidez S
    Blood Adv; 2023 Aug; 7(15):3978-3983. PubMed ID: 36129842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study.
    Mponda M; Kudowa E; Craven DM; Eastburg LC; Chikasema M; Kasonkanji E; Tomoka T; Roush SM; Simwinga L; Mumba N; Gopal S; Fedoriw Y; Painschab MS
    EClinicalMedicine; 2024 Mar; 69():102480. PubMed ID: 38356728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China.
    Xiao L; Wang C; Ma S; Wang Y; Guan L; Wu J; Zhang W; Liu Y; Wu Y
    Infect Agent Cancer; 2024 Apr; 19(1):12. PubMed ID: 38622727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Early Stages Hodgkin Lymphoma During Pregnancy.
    Avilés A; Nambo MJ; Neri N
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018006. PubMed ID: 29326803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.
    Zi Z; Du S; Zhang L; Wang Y; Ding L; Zhang C; Wang H; Pawlicki J; Cai Y; Yao Y; Zhou F; Tong Y; Riley JL; Cai Q; Ma X; Wei F
    Blood Adv; 2023 Aug; 7(15):4049-4063. PubMed ID: 36763539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
    Thieblemont C; Altmann B; Frontzek F; Renaud L; Chartier L; Ketterer N; Récher C; Poeschel V; Fitoussi O; Held G; Casasnovas O; Haioun C; Morschhauser F; Glass B; Mounier N; Tilly H; Rosenwald A; Ott G; Lenz G; Molina T; Ziepert M; Schmitz N
    Blood Adv; 2023 Aug; 7(15):3968-3977. PubMed ID: 36716220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity.
    Le K; Sun J; Ghaemmaghami J; Smith MR; Ip WKE; Phillips T; Gupta M
    Blood Adv; 2023 Aug; 7(15):3952-3967. PubMed ID: 36630565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.
    Aaroe A; Kurzrock R; Goyal G; Goodman AM; Patel H; Ruan G; Ulaner G; Young J; Li Z; Dustin D; Go RS; Diamond EL; Janku F
    Blood Adv; 2023 Aug; 7(15):3984-3992. PubMed ID: 36857436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of the PEGeD diagnostic algorithm for suspected pulmonary embolism in an independent cohort.
    Robert-Ebadi H; Roy PM; Sanchez O; Verschuren F; Le Gal G; Righini M
    Blood Adv; 2023 Aug; 7(15):3946-3951. PubMed ID: 36521170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-148a-3p and DDX6 functional link promotes survival of myeloid leukemia cells.
    Ghashghaei M; Le CT; Shaalan H; Escano L; Yue M; Arsalan A; Rouhi A; Nguyen TA; Vu LP
    Blood Adv; 2023 Aug; 7(15):3846-3861. PubMed ID: 36322827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy.
    Cronin RM; Wuichet K; Ghafuri DL; Hodges B; Chopra M; He J; Niu X; Kassim AA; Wilkerson K; Rodeghier M; DeBaun MR
    Blood Adv; 2023 Aug; 7(15):3775-3782. PubMed ID: 36350716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia.
    Fingrut WB; Gyurkocza B; Flynn J; Davis E; Devlin S; Scaradavou A; Chinapen S; Quach S; Cho C; Giralt SA; Jakubowski AA; Lin RJ; Papadopoulos EB; Perales MA; Ponce D; Shaffer BC; Tamari R; Young JW; Politikos I; Barker JN
    Blood Adv; 2023 Aug; 7(15):3824-3833. PubMed ID: 36240477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors.
    Bashey A; Zhang X; Morris LE; Holland HK; Bachier-Rodriguez L; Solomon SR; Solh M
    Blood Adv; 2023 Aug; 7(15):3816-3823. PubMed ID: 36961350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice.
    Nakai T; Iwamura Y; Kato K; Hirano I; Matsumoto Y; Tomioka Y; Yamamoto M; Suzuki N
    Blood Adv; 2023 Aug; 7(15):3793-3805. PubMed ID: 37146271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence.
    Cançado RD; Costa FF; Lobo C; Migliavaca CB; Falavigna M; Souza Filho HCR; Bueno CT; Silva-Pinto AC
    Blood Adv; 2023 Aug; 7(15):3783-3792. PubMed ID: 37104056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipients.
    Fingrut WB; Chinapen S; Flynn J; Katrichis A; Stewart M; Davis E; Shaffer BC; Shah GL; Barker JN
    Blood Adv; 2023 Aug; 7(15):3834-3837. PubMed ID: 37083929
    [No Abstract]   [Full Text] [Related]  

  • 17. Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia.
    Afzal A; Fiala MA; Jacoby MA; Walter MJ
    Blood Adv; 2023 Aug; 7(15):3838-3841. PubMed ID: 37042968
    [No Abstract]   [Full Text] [Related]  

  • 18. Teclistamab impairs detection of BCMA CAR-T cells.
    Glatte B; Wenk K; Grahnert A; Friedrich M; Merz M; Vucinic V; Fischer L; Reiche K; Alb M; Hudecek M; Franz P; Fricke S; Platzbecker U; Koehl U; Sack U; Boldt A; Hauschildt S; Weiss R
    Blood Adv; 2023 Aug; 7(15):3842-3845. PubMed ID: 37026812
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
    Rosiñol L; Oriol A; Ríos R; Blanchard MJ; Jarque I; Bargay J; Hernández MT; Cabañas V; Carrillo-Cruz E; Sureda A; Martínez-López J; Krsnik I; González ME; Casado LF; Martí JM; Encinas C; de Arriba F; Palomera L; Sampol A; González-Montes Y; Cabezudo E; Paiva B; Puig N; Cedena MT; de la Cruz J; Mateos MV; San Miguel J; Lahuerta JJ; Bladé J
    Blood; 2023 Nov; 142(18):1518-1528. PubMed ID: 37506339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poverty and relapse risk in children with acute lymphoblastic leukemia: a Children's Oncology Group study AALL03N1 report.
    Wadhwa A; Chen Y; Hageman L; Hoppmann A; Angiolillo A; Dickens DS; Neglia JP; Ravindranath Y; Ritchey AK; Termuhlen A; Wong FL; Landier W; Bhatia S
    Blood; 2023 Jul; 142(3):221-229. PubMed ID: 37070673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.